CSIMarket
 
Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 
 

Cytokinetics Incorporated's Suppliers Performance

CYTK's Supply Chain

 
CYTK Costs vs Sales of Suppliers Growth

More on CYTK Suppliers






  News about Cytokinetics Incorporated Contracts

Cytokinetics and Royalty Pharma Join Forces to Propel Specialty Cardiology Franchise

In a significant move to support the commercial launch of their groundbreaking drug, Aficamten, and bolster their research and development (RandD) pipeline, Cytokinetics, a leading biopharmaceutical company, has announced an expanded strategic funding collaboration with Royalty Pharma. The collaboration is set to provide Cytokinetics with up to $575 million in capital while diversifying the company's access to funding sources.The primary of this collaboration is to propel Cytokinetics' specialty cardiology franchise forward, paving the way for the successful commercial launch of Aficamten. This drug is specifically designed to tackle obstructive hypertrophic cardiomyopathy (oHCM), a condition characterized ...

Cytokinetics Announces Crucial Development in Pediatric Cardiology Treatment: Clinical Trial of Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Now Open for Enrollment

Cytokinetics, Incorporated, a pioneer in the biopharmaceutical industry, has recently announced that its CEDAR-HCM (Clinical Evaluation of Dosing with aficamten to Reduce Obstruction in a Pediatric Population in HCM) clinical trial is officially open for enrollment. The inaugural announcement was made in South San Francisco on May 08, 2024, marking a significant milestone for the potentially transformative treatment of hypertrophic cardiomyopathy (HCM) in the pediatric demographic.Aficamten, the primary molecule under study in this trial, is considered a next-in-class cardiac myosin inhibitor. Cytokinetics is currently developing this potential treatment explicitly for HCM, a relatively common genetic disord...




Cytokinetics Incorporated's Comment on Supply Chain









CYTK's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Cytokinetics Incorporated 5,366.70 7.82 -526.73 202
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com